SPA go-ahead for Argos Therapeutics' lead immunotherapeutic
This article was originally published in Scrip
Executive Summary
Argos Therapeutics will being dosing patients in a Phase III study of its lead product, the personalised immunotherapy AGS-003, by the end of this year after the US FDA agreed to a revised Special Protocol Assessment for the trial in metastatic renal cell carcinoma.